Founded in 2016, Foghorn Therapeutics discovers and develops novel drugs to treat cancer and other serious medical disorders. The company seeks to develop innovative therapeutics that target chromatin remodeling complexes. Foghorn leverages a proprietary platform based on revolutionary advances in the mechanistic understanding of genetically defined diseases.
The successful candidate will be responsible for driving the design and synthesis of small-molecule drug candidates at all stages of drug discovery. As part of the medicinal chemistry team, the successful candidate will analyze diverse data sets to build structure-activity relationships (SAR) that will then inform design hypotheses and medicinal chemistry strategy.